𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Scribed by Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM-MD-11AB Study Group

Publisher
Springer
Year
2007
Tongue
English
Weight
142 KB
Volume
254
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of rivastigmine
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
✍ Jason T. Olin; Vinod Bhatnagar; Patricio Reyes; Barbara Koumaras; Xiangyi Meng; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

## Abstract ## Objective Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild‐to‐moderate Alzheimer's disease (AD) and Parkinson's disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects an

Safety and tolerability of once-daily ve
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
✍ Roy W. Jones; Antony Bayer; Fraser Inglis; Andrew Barker; Ravinder Phul 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## Objective To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD). ## Method This 12‐week, randomised, double‐blind study, investigated three dosing schedules of memantine: OD1 (20 mg once

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Open-label flexible-dose pilot study to
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr

Efficacy and safety of donepezil over 3
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre